Advancing a vaccine to prevent human schistosomiasis

Vaccine

Volumn 34, Issue 26, 2016, Pages 2988-2991

  Merrifield, Maureen ^a,b   Hotez, Peter J ^a,b,c,d   Beaumier, Coreen M ^a,c   Gillespie, Portia ^a,c   Strych, Ulrich ^a,c   Hayward, Tara ^b   Bottazzi, Maria Elena ^a,b,c,d  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b SABIN VACCINE INSTITUTE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d BAYLOR UNIVERSITY   (United States)

Author keywords

Neglected tropical disease; Schistosomiasis; Vaccine

Indexed keywords

BILHVAX; RECOMBINANT VACCINE; SCHISTOSOMA VACCINE; SM 14; SM TSP 2; UNCLASSIFIED DRUG; 28-KILODALTON GLUTATHIONE S-TRANSFERASE ANTIGEN, SCHISTOSOMA MANSONI; BACTERIAL ANTIGEN; FATTY ACID TRANSPORTER; GLUTATHIONE TRANSFERASE; HELMINTH PROTEIN; PARASITE ANTIGEN; SM14 PROTEIN, SCHISTOSOMA MANSONI; TETRASPANIN; TSP-2 PROTEIN, SCHISTOSOMA MANSONI; VACCINE;

ARTICLE; BIOINFORMATICS; DRUG RESEARCH; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRODUCT DEVELOPMENT; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; VACCINATION; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; MEDICAL RESEARCH; PRIMATE; TRENDS;

ANIMALS; ANTIGENS, BACTERIAL; ANTIGENS, HELMINTH; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; FATTY ACID TRANSPORT PROTEINS; GLUTATHIONE TRANSFERASE; HELMINTH PROTEINS; HUMANS; PRIMATES; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; TETRASPANINS; VACCINES; VACCINES, SYNTHETIC;

EID: 84963585223     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.03.079     Document Type: Article

References (41)

1. Hotez P.J., Alvarado M., Basanez M.G., Bolliger I., Bourne R., Boussinesq M., et al. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis 2014, 8:e2865.
2. WHO Schistosomiasis - PCT database 2015.
3. Boissier J., Mone H., Mitta G., Bargues M.D., Molyneux D., Mas-Coma S. Schistosomiasis reaches Europe. Lancet Infect Dis 2015, 15:757-758.
4. King C.H. Parasites and poverty: the case of schistosomiasis. Acta Trop 2010, 113:95-104.
5. King C.H. It's time to dispel the myth of asymptomatic schistosomiasis. PLoS Negl Trop Dis 2015, 9:e0003504.
6. Kjetland E.F., Hegertun I.E., Baay M.F., Onsrud M., Ndhlovu P.D., Taylor M. Genital schistosomiasis and its unacknowledged role on HIV transmission in the STD intervention studies. Int J STD AIDS 2014, 25:705-715.
7. Ndeffo Mbah M.L., Kjetland E.F., Atkins K.E., Poolman E.M., Orenstein E.W., Meyers L.A., et al. Cost-effectiveness of a community-based intervention for reducing the transmission of Schistosoma haematobium and HIV in Africa. Proc Natl Acad Sci USA 2013, 110:7952-7957.
8. Ndeffo Mbah M.L., Skrip L., Greenhalgh S., Hotez P., Galvani A.P. Impact of Schistosoma mansoni on malaria transmission in Sub-Saharan Africa. PLoS Negl Trop Dis 2014, 8:e3234.
9. Honeycutt J., Hammam O., Fu C.L., Hsieh M.H. Controversies and challenges in research on urogenital schistosomiasis-associated bladder cancer. Trends Parasitol 2014, 30:324-332.
10. Global Burden of Disease Study Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 386:743-800.
11. Keenan J.D., Hotez P.J., Amza A., Stoller N.E., Gaynor B.D., Porco T.C., et al. Elimination and eradication of neglected tropical diseases with mass drug administrations: a survey of experts. PLoS Negl Trop Dis 2013, 7:e2562.
12. McManus D.P., Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008, 21:225-242.
13. Cioli D., Pica-Mattoccia L., Basso A., Guidi A. Schistosomiasis control: praziquantel forever. Mol Biochem Parasitol 2014, 195:23-29.
14. Mo A.X., Agosti J.M., Walson J.L., Hall B.F., Gordon L. Schistosomiasis elimination strategies and potential role of a vaccine in achieving global health goals. Am J Trop Med Hyg 2014, 90:54-60.
15. Ricciardi A., Ndao M. Still hope for schistosomiasis vaccine. Hum Vaccines Immunother 2015, 11:2504-2508.
16. Coulson P.S. The radiation-attenuated vaccine against schistosomes in animal models: paradigm for a human vaccine. Adv Parasitol 1997, 39:271-336.
17. Coulson P.S., Wilson R.A. Recruitment of lymphocytes to the lung through vaccination enhances the immunity of mice exposed to irradiated schistosomes. Infect Immun 1997, 65:42-48.
18. Kariuki T.M., Farah I.O., Yole D.S., Mwenda J.M., Van Dam G.J., Deelder A.M., et al. Parameters of the attenuated schistosome vaccine evaluated in the olive baboon. Infect Immun 2004, 72:5526-5529.
19. Wilson R.A., Coulson P.S., Mountford A.P. Immune responses to the radiation-attenuated schistosome vaccine: what can we learn from knock-out mice. Immunol Lett 1999, 65:117-123.
20. Mountford A.P., Anderson S., Wilson R.A. Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant. J Immunol 1996, 156:4739-4745.
21. Wynn T.A., Jankovic D., Hieny S., Cheever A.W., Sher A. IL-12 enhances vaccine-induced immunity to Schistosoma mansoni in mice and decreases T helper 2 cytokine expression, IgE production, and tissue eosinophilia. J Immunol 1995, 154:4701-4709.
22. Pearson M.S., Becker L., Driguez P., Young N.D., Gaze S., Mendes T., et al. Of monkeys and men: immunomic profiling of sera from humans and non-human primates resistant to schistosomiasis reveals novel potential vaccine candidates. Front Immunol 2015, 6:213.
23. Sotillo J., Pearson M., Becker L., Mulvenna J., Loukas A. A quantitative proteomic analysis of the tegumental proteins from Schistosoma mansoni schistosomula reveals novel potential therapeutic targets. Int J Parasitol 2015, 45:505-516.
24. Driguez P., Doolan D.L., Molina D.M., Loukas A., Trieu A., Felgner P.L., et al. Protein microarrays for parasite antigen discovery. Methods Mol Biol 2015, 1201:221-233.
25. Beniguel L., Diallo T.O., Remoue F., Williams D.L., Cognasse F., Charrier-Mze N., et al. Differential production in vitro of antigen specific IgG1, IgG3 and IgA: a study in Schistosoma haematobium infected individuals. Parasite Immunol 2003, 25:39-44.
26. Riveau G., Deplanque D., Remoue F., Schacht A.M., Vodougnon H., Capron M., et al. Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl Trop Dis 2012, 6:e1704.
27. ClinicalTrials.gov. Efficacy of Vaccine Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical Recurrences of Schistosoma Haematobium Pathology (Bilhvax).
28. Tran M.H., Pearson M.S., Bethony J.M., Smyth D.J., Jones M.K., Duke M., et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 2006, 12:835-840.
29. Cheng W., Curti E., Rezende W.C., Kwityn C., Zhan B., Gillespie P., et al. Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis. Hum Vaccines Immunother 2013, 9:2351-2361.
30. Curti E., Kwityn C., Zhan B., Gillespie P., Brelsford J., Deumic V., et al. Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis. Hum Vaccines Immunother 2013, 9:2342-2350.
31. Tendler M., Almeida M., Simpson A. Development of the Brazilian anti schistosomiasis vaccine based on the recombinant fatty acid binding protein Sm14 Plus GLA-SE adjuvant. Front Immunol 2015, 6:218.
32. Karmakar S., Zhang W., Ahmad G., Torben W., Alam M.U., Le L., et al. Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons. Vaccine 2014, 32:1296-1303.
33. Da'dara A.A., Li Y.S., Xiong T., Zhou J., Williams G.M., McManus D.P., et al. DNA-based vaccines protect against zoonotic schistosomiasis in water buffalo. Vaccine 2008, 26:3617-3625.
34. Hotez P.J., Bethony J.M., Diemert D.J., Pearson M., Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 2010, 8:814-826.
35. Bergquist N.R., Leonardo L.R., Mitchell G.F. Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach. Trends Parasitol 2005, 21:112-117.
36. Zhang W., Ahmad G., Le L., Rojo J.U., Karmakar S., Tillery K.A., et al. Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon. Parasitol Res 2014, 113:2239-2250.
37. Gaze S., Driguez P., Pearson M.S., Mendes T., Doolan D.L., Trieu A., et al. An immunomics approach to schistosome antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas. PLoS Pathog 2014, 10:e1004033.
38. Tran M.H., Freitas T.C., Cooper L., Gaze S., Gatton M.L., Jones M.K., et al. Suppression of mRNAs encoding tegument tetraspanins from Schistosoma mansoni results in impaired tegument turnover. PLoS Pathogens 2010, 6:e1000840.
39. ® with or without GLA-AF for intestinal schistosomiasis in healthy adults 2015.
40. ClinicalTrials.gov Study to evaluate the safety of the vaccine prepared sm14 against schistosomiasis 2013.
41. "G-Finder". G-Finder. Policy cures.